Abstract：
:Since the introduction of biomarkers in the late 1980s, considerable research has been dedicated to their validation and application. As a result, many biomarkers are now commonly used in clinical practice. However, the role of biomarkers in the prediction of right ventricular failure (RVF) and in the prognostication for patients with RVF remains underexplored. Barriers include a lack of awareness of the importance of right ventricular function, especially in the perioperative setting, as well as a lack of reproducible means to assess right ventricular function in this setting. We provide an overview of biomarkers with right ventricular prognostic capabilities that could be further explored in patients expecting cardiac surgery, who are notoriously susceptible to developing RVF. We discuss biomarkers' mechanistic pathways and highlight their potential strengths and weaknesses in use in research and clinical care.
journal_name
J Card Failjournal_title
Journal of cardiac failureauthors
Jabagi H,Ruel M,Sun LYdoi
10.1016/j.cardfail.2019.09.007subject
Has Abstractpub_date
2020-09-01 00:00:00pages
776-780issue
9eissn
1071-9164issn
1532-8414pii
S1071-9164(19)30516-0journal_volume
26pub_type
杂志文章abstract：OBJECTIVE:The aim of this work was to determine whether adrenergic-induced left ventricular (LV) dilation and eccentric remodeling in pressure-overload hypertrophy is sex specific. METHODS AND RESULTS:Chronic β-adrenoreceptor activation was produced in male and female spontaneously hypertensive rats (SHRs) by means of...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2016.09.017
更新日期：2017-02-01 00:00:00
abstract：:Elevated plasma levels of endothelin (ET) have been reported to accompany the development of heart failure (HF), and therefore, this potent vasoconstrictive peptide has been postulated to contribute to the altered pulmonary hemodynamics that occur in this disease process. The overall goal of this study was to examine ...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/s1071-9164(97)90025-7
更新日期：1997-12-01 00:00:00
abstract：BACKGROUND:Progress has been made in addressing pain in specific diseases such as cancer, but less attention has focused on understanding pain in nonmalignant states, including heart failure (HF). METHODS AND RESULTS:From March 2006 to June 2007, 672 veterans were surveyed and scores for the Brief Pain Inventory, pain...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,多中心研究
doi：10.1016/j.cardfail.2008.09.002
更新日期：2009-02-01 00:00:00
abstract：BACKGROUND:Urinary liver-type fatty acid-binding protein (L-FABP) is a potential biomarker for acute kidney injury, and it in turn increases cardiovascular mortality. We tested whether the urinary L-FABP level predicted short- and mid-term outcomes in patients with acute heart failure. METHODS AND RESULTS:We enrolled ...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2018.07.003
更新日期：2018-08-01 00:00:00
abstract：BACKGROUND:Survival of patients with congenital heart defects including increased right ventricular pressure load (ie, tetralogy of Fallot) or pulmonary hypertension is dependent on the function of the right ventricle (RV). RV remodeling has several effects with progressive transition from compensated status to heart f...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2020.02.006
更新日期：2020-07-01 00:00:00
abstract：BACKGROUND:Despite ample data from randomized clinical trials (RCTs), the management of advanced heart failure (HF) varies greatly. We examined the most common refractory questions arising in routine inpatient management of advanced HF. METHODS:From the inpatient HF service at 1 hospital, we prospectively recorded cli...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2003.10.006
更新日期：2004-06-01 00:00:00
abstract：BACKGROUND:Although beta-blockers were well-tolerated by heart failure (HF) patients in clinical trials, tolerability of these drugs in a general population of HF patients is not well-described. METHODS:We studied a total of 308 encounters with beta-blockers therapy in 268 ambulatory HF patients. Side effects and freq...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,多中心研究
doi：10.1054/jcaf.2003.34
更新日期：2003-06-01 00:00:00
abstract：BACKGROUND:In chronic heart failure (CHF), persistent autonomic derangement and neurohumoral activation cause structural end-organ damage, decrease exercise capacity, and reduce quality of life. Beneficial effects of pharmacotherapy and of exercise training in CHF have been documented at various functional and structur...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,评审
doi：10.1016/j.cardfail.2006.12.006
更新日期：2007-05-01 00:00:00
abstract：OBJECTIVE:Disease management programs (DMPs) may reduce short-term readmission or death after heart failure (HF) hospitalization. We sought to determine if targeting of DMP to the highest-risk patients could improve efficiency. METHODS AND RESULTS:Patients (n = 412) admitted with HF were randomized to usual care or an...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.cardfail.2019.01.015
更新日期：2019-05-01 00:00:00
abstract：:The authors have previously shown that the resistance ratio (RR) is increased in patients with congestive heart failure (CHF), and that the patients with the highest RRs have an increased mortality. The authors hypothesized that CHF patients with the lowest maximum oxygen consumption and the most impaired Weber functi...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/1071-9164(94)90005-1
更新日期：1994-10-01 00:00:00
abstract：BACKGROUND:Tissue kallikrein is a serine proteinase that generates the vasoactive kinin peptide, which produces vasodilatory, angiogenic, and antiapoptotic effects. In this study, we investigated the effect of a stable supply of kallikrein and kinin on ventricular remodeling and blood vessel growth in rats after myocar...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2007.04.009
更新日期：2007-09-01 00:00:00
abstract：BACKGROUND:Reduced left ventricular systolic function predicts worse outcomes. However, the optimal threshold for "normal" left ventricular ejection fraction (LVEF) is uncertain. In general, LVEF ≥ 55% is considered to be "normal" by guidelines, with a low normal designation for LVEF being 50%-55%. We assessed the prog...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2016.03.013
更新日期：2016-10-01 00:00:00
abstract：BACKGROUND:We sought to systematically combine the evidence on efficacy of disease management programs (DMPs) in the treatment of congestive heart failure (CHF), to identify and explain heterogeneity of results from prior studies of DMPs, and to assess potential publication bias from these studies. METHODS AND RESULTS...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,meta分析,评审
doi：10.1016/j.cardfail.2006.03.003
更新日期：2006-09-01 00:00:00
abstract：BACKGROUND:The addition of an angiotensin receptor blocker (ARB) to an angiotensin-converting enzyme inhibitor (ACEI) in patients with heart failure remains controversial. A recent meta-analysis showed that the combination therapy reduces hospitalization without improved survival. Whether excess risk is associated with...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,meta分析,评审
doi：10.1016/j.cardfail.2007.11.008
更新日期：2008-04-01 00:00:00
abstract：BACKGROUND:Studies have shown that neither ejection fraction nor hemodynamic abnormalities during exercise in chronic heart failure (HF) correlate with symptoms of fatigue and exhaustion. The concept that exercise limitation in patients with chronic HF is due to abnormal hemodynamics during exercise has been revised to...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,评审
doi：10.1016/j.cardfail.2005.03.002
更新日期：2005-09-01 00:00:00
abstract：BACKGROUND:Chronic heart failure is a disease syndrome characterized in its advanced stages by a poor quality of life, frequent hospitalizations, and a high risk of mortality. In advanced and ultra-advanced chronic heart failure, many treatment options, such as cardiac transplantation and mechanical devices, are severe...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2005.10.013
更新日期：2005-12-01 00:00:00
abstract：BACKGROUND:Circulating pro-angiogenic cells (PACs) contribute to vascular and myocardial regeneration. A low level of PACs is associated with worse outcome in patients with coronary heart disease. However, little is known about PACs in heart failure (HF). METHODS AND RESULTS:Blood was sampled at baseline in 111 patien...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,多中心研究
doi：10.1016/j.cardfail.2009.05.011
更新日期：2009-11-01 00:00:00
abstract：BACKGROUND:Patients having heart failure with midrange ejection fraction (HFmrEF: 40% ≤ EF < 50%) are increasingly being considered a new subset of the population with heart failure. Despite recent advances in heart-failure treatment strategies, the prognosis of these patients has not improved substantially over time. ...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,多中心研究
doi：10.1016/j.cardfail.2019.05.010
更新日期：2019-08-01 00:00:00
abstract：BACKGROUND:Recovery of ventricular function during left ventricular assist device (LVAD) support allowing device explantation occurs infrequently. We explored the hypothesis that certain patient profiles are more likely to exhibit LV recovery during LVAD support. METHODS AND RESULTS:A retrospective analysis of data fr...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.cardfail.2012.01.020
更新日期：2012-05-01 00:00:00
abstract：BACKGROUND:The definition of response to cardiac resynchronization therapy (CRT) remains controversial, with variable rates of response depending on the criteria used. Our aim was to analyze the impact of CRT on diastolic function in different degrees of response, particularly in patients with positive clinical but no ...
journal_title：Journal of cardiac failure
pub_type： 更正并重新发布的文章,杂志文章
doi：10.1016/j.cardfail.2013.11.001
更新日期：2013-12-01 00:00:00
abstract：:Beta-adrenergic blocking agents are standard treatment for patients with mild-to-moderate heart failure. When patients receiving beta-blockers decompensate they often need treatment with a positive inotropic agent. The beta-agonist dobutamine may not produce much increase in cardiac output during full-dose beta-blocke...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,评审
doi：10.1054/jcaf.2001.26655
更新日期：2001-06-01 00:00:00
abstract：BACKGROUND:Acute dyspnea poses a diagnostic challenge for physicians, and the current methods in differentiating cardiac from non-cardiac causes have been limited to date. Recently, the brain natriuretic peptide (BNP) rapid test has been validated in the emergency room. Nevertheless, the early accumulation of fluid in ...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2008.04.005
更新日期：2008-10-01 00:00:00
abstract：BACKGROUND:In patients with heart failure and preserved ejection fraction (HF-PEF) randomized in the Americas as part of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, treatment with spironolactone enhanced the risk of hyperkalemia but reduced the risk of hypoka...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.cardfail.2018.03.002
更新日期：2018-05-01 00:00:00
abstract：BACKGROUND:This is the first study to examine the effect of acute (24-hour) beta-blocker withholding on ventilatory efficiency in patients with advanced chronic heart failure (CHF) during maximal incremental treadmill cardiopulmonary exercise test. METHODS AND RESULTS:Seventeen CHF patients were studied either 3 hours...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.cardfail.2010.02.006
更新日期：2010-07-01 00:00:00
abstract：BACKGROUND:Fulminant myocarditis (FM) is a rare but life-threatening disease. Intravenous immunoglobulin (IVIG) is not recommended for acute or chronic myocarditis in Western nations owing to the lack of rigorous evidence, but it is widely used in other countries, including Japan. This nationwide retrospective cohort s...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2015.01.004
更新日期：2015-05-01 00:00:00
abstract：:Contracting myocytes are highly variable in size and generally resemble elliptical cylinders in shape. Although their arrangement within the ventricular wall is rather complex, their length runs in a tangential manner, and their transverse axis runs transmurally. Consequently, it was proposed many years ago that chang...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1054/jcaf.2002.129280
更新日期：2002-12-01 00:00:00
abstract：BACKGROUND:Fixed pulmonary hypertension is common in patients with advanced heart failure and is a contraindication for heart transplantation. Left ventricular assist devices (LVAD) and inotropes have been used to reduce pulmonary vascular resistance (PVR) and allow transplantation. However, little is known about the e...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2016.06.421
更新日期：2017-03-01 00:00:00
abstract：:The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, ...
journal_title：Journal of cardiac failure
pub_type：
doi：10.1016/j.cardfail.2013.05.012
更新日期：2013-08-01 00:00:00
abstract：OBJECTIVES:There have been no published recommendations about staffing needs for a heart failure (HF) clinic or an office setting focused on heart transplant. The goal of this survey was to understand the current staffing environment of HF, transplant, and mechanical circulatory support device (MCSD) programs in the Un...
journal_title：Journal of cardiac failure
pub_type： 杂志文章,多中心研究
doi：10.1016/j.cardfail.2011.04.001
更新日期：2011-05-01 00:00:00
abstract：:Carfilzomib is a novel irreversible proteasome inhibitor (PI) used with increasing frequency to treat patients with relapsed and/or refractory multiple myeloma (RRMM). This agent is an effective treatment for this challenging population, but proteasome inhibition has the potential of significant cardiac toxicity via t...
journal_title：Journal of cardiac failure
pub_type： 杂志文章
doi：10.1016/j.cardfail.2014.11.008
更新日期：2015-02-01 00:00:00
